GILEAD SCIENCES, INC. is 9.7x more valuable than NEUROCRINE BIOSCIENCES INC by market capitalization ($155.93 B vs $16.06 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | NBIX | GILD |
|---|---|---|
| Market cap | $16.06 B | $155.93 B |
| US-listed rank | #712 | #98 |
| Revenue (latest FY) | $2.86B | $29.44B |
| Net income (latest FY) | $478.60M | $8.51B |
| Net margin | 16.7% | 28.9% |
| P/E (trailing FY) | 33.6 | 18.3 |
| SEC filings | 2,097 | 981 |
GILEAD SCIENCES, INC. is 9.7x more valuable than NEUROCRINE BIOSCIENCES INC by market capitalization ($155.93 B vs $16.06 B).
In their latest fiscal years, NEUROCRINE BIOSCIENCES INC reported $2.86B in revenue while GILEAD SCIENCES, INC. reported $29.44B.
Full pages: NEUROCRINE BIOSCIENCES INC and GILEAD SCIENCES, INC., or browse the full rankings.